Hepatic Disease in Patients With HIV

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 11/13/21 (What's New)

Summary

  • AASLD/IDSA guidance panel recommends highly active DAA regimens as preferred therapy for HCV treatment of persons with HIV and genotype 2-6 HCV coinfection (Table 10) (Management Guidelines)[AASLD-IDSA HCV]
  • EASL guidance panel recommends highly active DAA regimens for HCV treatment of persons with HIV and genotype 2-6 HCV coinfection (Table 11) (Management Guidelines)[EASL HCV]

Action required

Keywords: Hepatic Complications, Special Populations, Treatment Complications, Viral Hepatitis Coinfection

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.